Who are MCC-TT's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Prevnar 20, MenACWY-DT, PCV13 alone, Meningococcal C, Meningococcal A+C vaccine, Menveo®/Menactra®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mcc-tt.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

MCC-TT — Competitive Intelligence Brief

MCC-TT (MCC-TT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Conjugate vaccine. Area: Immunology / Infectious Disease.

phase 3 Conjugate vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

MCC-TT (MCC-TT) — MCM Vaccines B.V.. MCC-TT is a therapeutic vaccine designed to stimulate immune responses against meningococcal and tetanus pathogens through conjugate technology.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MCC-TT TARGET	MCC-TT	MCM Vaccines B.V.	phase 3	Conjugate vaccine
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
MenACWY-DT	MenACWY-DT	Canadian Immunization Research Network	marketed	Conjugate vaccine	Neisseria meningitidis capsular polysaccharides (serogroups A, C, W, Y)
PCV13 alone	PCV13 alone	Korea University Guro Hospital	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide capsule (13 serotypes)
Meningococcal C	Meningococcal C	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Conjugate vaccine	Neisseria meningitidis serogroup C polysaccharide capsule
Meningococcal A+C vaccine	Meningococcal A+C vaccine	Sanofi Pasteur, a Sanofi Company	marketed	Polysaccharide conjugate vaccine	Neisseria meningitidis serogroups A and C capsular polysaccharides
Menveo®/Menactra®	Menveo®/Menactra®	Massachusetts General Hospital	marketed	Conjugate vaccine	Neisseria meningitidis serogroups A, C, W, and Y

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Conjugate vaccine class)

GlaxoSmithKline · 26 drugs in this class
Sanofi Pasteur, a Sanofi Company · 6 drugs in this class
CanSino Biologics Inc. · 3 drugs in this class
MCM Vaccines B.V. · 3 drugs in this class
Beijing Minhai Biotechnology Co., Ltd · 3 drugs in this class
Wyeth is now a wholly owned subsidiary of Pfizer · 2 drugs in this class
PT Bio Farma · 2 drugs in this class
LG Life Sciences · 2 drugs in this class
Walvax Biotechnology Co., Ltd. · 2 drugs in this class
Heinrich-Heine University, Duesseldorf · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MCC-TT — Competitive Intelligence Brief. https://druglandscape.com/ci/mcc-tt. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab